OA01.03 Fc?RIIa rs10800309 polymorphism is a HLA-B57 and HLA-B27 independent predictor of HIV controlOral Abstract SessionHumoral immunity
OA01.04 Serum IgA inhibits HIV-specific broadly neutralising antibody Fc functionsOral Abstract SessionBroadly neutralizing antibodies
OA01.05LB Opening the HIV-1 envelope for neutralization and antibody-dependent cellular cytotoxicityOral Abstract SessionTherapeutic vaccines, viral reservoirs and eradication/remission
OA02.01 Profiling the HIV epidemic with recency of infection instead of recency of diagnosis: 2 years of experience in North Carolina, USAOral Abstract SessionEpidemiology of HIV
OA02.02 Correlates of high HIV transmission areas in a generalized hyperendemic setting: findings from a national survey in EswatiniOral Abstract SessionTreatment as prevention
OA02.03 Progress toward HIV elimination goals: trends in and projections of treatment as prevention strategy in 38 African countriesOral Abstract SessionTreatment as prevention
OA02.04 HIV prevalence and incidence among FSWs participanting in a HIV vaccine preparedness study in Dar es Salaam,TanzaniaOral Abstract SessionEpidemiology of HIV
OA02.05LB Risk factors for HIV transmission in heterosexual men, men who have sex with men, and transgender women participating in the HVTN 702 'Uhambo' and HVTN 503/503-S 'Phambili' HIV vaccine trialsOral Abstract SessionTransmission of HIV
OA03.01 Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and dosesOral Abstract SessionClinical trial results
OA03.02 Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed InfantsOral Abstract SessionBroadly neutralizing antibodies
seek-warrow-warrow-eseek-e81 - 90 of 444 items